DANOCRINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Danocrine, and what generic alternatives are available?
Danocrine is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in DANOCRINE is danazol. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the danazol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Danocrine
A generic version of DANOCRINE was approved as danazol by BARR on August 9th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DANOCRINE?
- What are the global sales for DANOCRINE?
- What is Average Wholesale Price for DANOCRINE?
Summary for DANOCRINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 53 |
Clinical Trials: | 6 |
Patent Applications: | 4,583 |
DailyMed Link: | DANOCRINE at DailyMed |
Recent Clinical Trials for DANOCRINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sierra Oncology, Inc. | Phase 3 |
Peking University People's Hospital | Phase 1/Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for DANOCRINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |